NVX-Cov2373 Novavax Covid-19 vaccine: A further analysis of its efficacy using multiple modes of expressionArticle Published on 2022-12-012022-11-16 Journal: Fundamental & clinical pharmacology [Category] 변종, [키워드] absolute risk reduction age analysed Analysis Characteristics clinical trial COVID-19 vaccines description Efficacy Europe expression NNT Novavax number needed to treat NVX-CoV2373 NVX-Cov2373 Covid-19 vaccine parameter parameters reduction Relative risk. risk treat Vaccine variant [DOI] 10.1111/fcp.12794 PMC 바로가기
NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responsesArticle Published on 2022-10-032022-11-15 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Adaptive immunity CD4+ CD4+ T cell CD4+ T cells CD8+ T cell Cell Cellular immune response characteristic characterization circulating correlated COVID-19 demonstrated detectable dose Efficacy follicular full-length SARS-CoV-2 functional humoral immune responses IFN-γ immune immunization immunology individual induce magnitude Matrix-M NVX-CoV2373 Protective Protein response responses robust SARS-CoV-2-neutralizing antibody spike trimer subset T cells T cells. Th1 cell trials vaccinated individual vaccination Vaccine [DOI] 10.1172/JCI160898 PMC 바로가기
Protein vaccine NVX-CoV2373 elicits functional T cell immunityArticle Published on 2022-10-032022-11-15 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 진단, [키워드] Analysis Antibody Response association CD4+ CD4+ T cell CD8+ T cell Cell characterized circumvent dose Effect elicit elicited enrolled follicular functional humoral immune responses Immunity individual induce mRNA vaccine neutralizing antibody titers NVX-CoV2373 recognizing Region response robust SARS-CoV-2 antigen SARS-CoV-2 vaccine T cell T cell responses Trial Vaccine vaccine dose [DOI] 10.1172/JCI163614 PMC 바로가기
A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine RegimensArticle Published on 2022-09-012022-11-16 Journal: Pharmaceutical research [Category] 변종, [키워드] B cell responses BBIBP-CorV caused clinical trial convalescent convalescent individual convalescent individuals CoronaVac COVID-19 COVID-19 patients COVID-19 vaccine effective effective vaccine Efficacy Efficiency Health immune immune response Immunity Immunological response imperative implementation inactivated investigated long-lasting mechanism NVX-CoV2373 phase Prophylactic regimen regimens Reinfection reported response review RNA SARS-CoV-2 the vaccine transmission of SARS-CoV-2 Vaccine vaccine regimens. Vaccines variant virus [DOI] 10.1007/s11095-022-03323-w PMC 바로가기
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years – United States, July 202218세 이상인 사람의 Novavax COVID-19 백신 사용에 대한 예방접종 관행에 대한 자문 위원회의 임시 권고 - 미국, 2022년 7월Article Published on 2022-08-052022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] 95% CI Administered Adults Alpha variant assessments association authorization B.1.1.7 causal relationship cause Chain Reaction circulating Committee COVID-19 COVID-19 vaccine dose drug Efficacy efficacy analysis Emergency Emergency use authorization EUA FDA flexibility food Food and Drug Administration immunization infection with SARS-CoV-2 information Interim Matrix-M myocarditis Novavax NVX-CoV2373 per-protocol Pericarditis Person polymerase chain reaction Practice predominant PROTECT Protein provide reported reverse transcription Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 symptomatic symptomatic COVID-19 United States vaccination Vaccine vaccine efficacy variant virus [DOI] 10.15585/mmwr.mm7131a2 PMC 바로가기 [Article Type] Article
Humoral and cellular immune memory to four COVID-19 vaccines4가지 COVID-19 백신에 대한 체액 및 세포 면역 기억Article Published on 2022-07-072022-09-11 Journal: Cell [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Ad26 Ad26.COV2.S antibodies Antibody Response Antibody responses B cell BNT162b2 CD4 CD8 cellular cellular immunity comparable comparison COV2.S COVID-19 COVID-19 case COVID-19 vaccine COVID-19 vaccines CXCR3 deaths Decline detectable examined frequencies Frequency head Human humoral Humoral immunity immune memory immune memory. immune response immune responses immunization individual janssen memory memory B cells memory T Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 Multiple Novavax Novavax NVX-CoV2373 NVX-CoV2373 Pathogens Pfizer/BioNTech PROTECT protective immunity representing SARS-CoV2 subject symptomatic T cell T cells vaccination Vaccine vaccinee [DOI] 10.1016/j.cell.2022.05.022 PMC 바로가기 [Article Type] Article
Covid-19 vaccines and variants of concern: A reviewCovid-19 백신 및 우려 변종: 검토Review Published on 2022-07-012022-09-11 Journal: Reviews in Medical Virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad5-nCoV administration adverse event AZD1222 BBIBP-CorV BNT162b2 caused Cell-mediated immunity Clinical studies CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disease COVID-19 vaccination COVID-19 vaccines CVnCoV deaths effective vaccine Efficacy Infection mRNA mRNA vaccines mRNA-1273 Mutation nCoV Neutralising Antibodies neutralising antibody nine NVX-CoV2373 outbreak rare adverse events reported Research respiratory SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Spike protein Spread symptomatic COVID-19 symptomatic COVID-19 disease the SARS-CoV-2 vaccination Vaccine vaccine candidate vaccine candidates vaccine efficacy variant variants variants of concern variants of concern. Viral Viral vector viral vector and mRNA vaccines VOCs Wuhan-Hu-1 ZF2001 [DOI] 10.1002/rmv.2313 PMC 바로가기 [Article Type] Review
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial건강한 일본 성인을 대상으로 한 NVX-CoV2373(TAK-019) 백신의 안전성 및 면역원성: I/II상 무작위 대조 시험 중간 보고Clinical Trial Published on 2022-05-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% confidence interval Adults adverse event AEs age AMED anti-SARS-CoV-2 immune response antibody ARMS company conducted COVID-19 Data analysis demonstrated development dose enrolled evaluated Follow-up geometric healthy IgG immune response immunogenicity injection injection site pain Interim Japan Japanese Japanese adults Limited NVX-CoV2373 occurred outcome participant Participants pharmaceutical Placebo placebo-controlled trial Protein Randomized Randomized controlled trial receive reported robust Safety Safety. SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nanoparticle vaccine SARS-CoV-2 vaccine screened second dose seroconversion rate serum IgG stratified subject Takeda vaccination Vaccine [DOI] 10.1016/j.vaccine.2022.04.035 PMC 바로가기 [Article Type] Clinical Trial
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis우려되는 SARS-CoV-2 변종에 대한 COVID-19 백신의 효과: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-05-232022-09-11 Journal: BMC Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval Ad26 Ad26.COV2.S Alpha Alpha variant Analysis BBIBP-CorV Beta BNT162b2 booster vaccination calculated case-control studies case-control study ChAdOx1 CIs Cohort studies cohort study conducted controlled trials CoronaVac COV2.S COVID-19 COVID-19 vaccine COVID-19 vaccines CVnCoV defined Delta delta variant Delta variants effective Effectiveness estimate evaluated Evidence Gamma Interaction Meta-analysis moderate mRNA mRNA vaccine mRNA vaccines mRNA-1273 NVX-CoV2373 omicron Omicron variants Participants random-effect Random-effects meta-analysis Randomized controlled trial RCT RCTs SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SCB-2019 searched significant interaction systematic review vaccination Vaccine vaccine effectiveness variants variants of concern. VoC [DOI] 10.1186/s12916-022-02397-y PMC 바로가기 [Article Type] Meta-Analysis